NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Personalis CFO Aaron Tachibana sells $4,953 in stock

Published 20/11/2024, 22:26
PSNL
-

Aaron Tachibana, the Chief Financial Officer and Chief Operating Officer of Personalis, Inc. (NASDAQ:PSNL), recently sold 1,307 shares of the company's common stock. The transaction, executed on November 18, 2024, was completed at a weighted average price of approximately $3.79 per share, generating a total of $4,953.

According to the SEC filing, the shares were automatically sold to cover tax withholding obligations from the settlement of vested restricted stock units. Following this transaction, Tachibana retains direct ownership of 173,963 shares in Personalis. The sale price ranged from $3.76 to $3.79 per share.

In other recent news, Personalis, Inc. reported a significant 41% increase in revenue for the third quarter of 2024, amounting to $25.7 million. This increase was primarily due to a 96% surge in biopharma sector revenue, driven by a high demand for their tumor profiling products and the NeXT Personal MRD assay. The company also raised its full-year revenue guidance to between $83 million and $84 million, reflecting strong growth prospects. However, the company expects a decline in Q4 revenue to between $15 million and $16 million, mainly attributed to a decrease in revenue from Moderna (NASDAQ:MRNA) and Natera (NASDAQ:NTRA). Despite the projected decline, Personalis maintains a positive outlook, with plans to secure reimbursement for three indications by 2025 and an aspirational revenue target of $100 million. These are among the recent developments that have shaped the company's trajectory.

InvestingPro Insights

While Aaron Tachibana's recent stock sale was primarily to cover tax obligations, it's worth examining Personalis, Inc.'s current financial position to provide context for investors. According to InvestingPro data, Personalis has a market capitalization of $198.1 million USD, reflecting its status as a smaller player in the biotech sector.

Despite recent stock price volatility, with a significant 22.32% drop in the past week, Personalis has shown impressive growth over longer periods. The company's stock has delivered a remarkable 173.33% return over the past year, and a 152.74% return in the last six months. This performance suggests that while short-term fluctuations are present, the company has been gaining traction in the market.

From a financial perspective, Personalis is experiencing rapid growth, with revenue increasing by 40.89% in the most recent quarter. However, an InvestingPro Tip indicates that the company is quickly burning through cash, which aligns with its current unprofitable status. The operating income margin stands at -80.11%, highlighting the challenges Personalis faces in achieving profitability.

Another InvestingPro Tip notes that Personalis holds more cash than debt on its balance sheet, which could provide some financial flexibility as the company navigates its growth phase. This positive aspect is further supported by the fact that liquid assets exceed short-term obligations, potentially mitigating some of the risks associated with cash burn.

For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Personalis, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.